Dual-Targeted Drug Design of HER2 and HSP90 by CoMFA Model and Pharmacophore Analysis

# Equal contribution Abstract—Heat shock protein 90 (HSP90) and human epidermal growth factor receptor 2 protein (HER2) are involved in several signal pathways for cancer cell proliferation. We focused on these two hallmarkers to design the dual-targeted inhibitors for cancer therapy. The comparative molecular field analysis (CoMFA) and pharmacophore analysis were employed for generating the predictive models. According the leave-one out (LOO) cross- validation, the CoMFA models obtained the significant r2 values of 0.978 and 0.974 for HSP90 and HER2, respectively. The contour maps of both targets indicated that there were amount of similar bulky favors area. Besides, the cost difference of pharmacophore models was 48.539 for 70% correlation with the experiment. The queries at 3-N and 6-N position of purine-based compound had the similar distributions. This study provided important information for design the HER2 and HSP90 dual- targeted inhibitors

[1]  H. Hurwitz,et al.  Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Comoglio,et al.  The MET receptor tyrosine kinase in invasion and metastasis , 2007, Journal of cellular physiology.

[3]  Bruce L. Bush,et al.  Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA , 1993, J. Comput. Aided Mol. Des..

[4]  Gabriela Chiosis,et al.  Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. , 2005, Journal of medicinal chemistry.

[5]  Mahendra Awale,et al.  3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors. , 2008, Journal of molecular graphics & modelling.

[6]  F. Hartl,et al.  In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis , 1998, The Journal of cell biology.

[7]  James R. Porter,et al.  Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.

[8]  E. Coutinho,et al.  A CoMFA study of COX-2 inhibitors with receptor based alignment. , 2004, Journal of molecular graphics & modelling.

[9]  Maurizio Recanatini,et al.  Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. , 2007, Journal of medicinal chemistry.

[10]  D. Sawyer,et al.  Heat shock proteins in cancer: chaperones of tumorigenesis. , 2006, Trends in biochemical sciences.

[11]  G. Prentice,et al.  An evaluation of the Charm Test – a rapid method for the detection of penicillin in milk , 1983, Journal of Dairy Research.

[12]  A. Ryan,et al.  ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity , 2005, British Journal of Cancer.

[13]  Ralph Weissleder,et al.  Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment , 2007, International journal of cancer.